Elevated exhalation of hydrogen peroxide in patients with systemic sclerosis

被引:25
作者
Luczyñska, M
Szkudlarek, U
Dziankowska-Bartkowiak, B
Waszczykowska, E
Kasielski, M
Sysa-Jèdrzejowska, A
Nowak, D
机构
[1] Med Univ Lodz, Dept Expt & Clin Physiol, Inst Physiol & Biochem, PL-92215 Lodz, Poland
[2] Med Univ Lodz, Dept Dermatol, PL-92215 Lodz, Poland
[3] Med Univ Lodz, Pract Clin Training Ctr, PL-92215 Lodz, Poland
关键词
expired breath condensate; hydrogen peroxide; systemic sclerosis;
D O I
10.1046/j.1365-2362.2003.01138.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Systemic sclerosis is accompanied by an influx of activated phagocytes into distal airways. These cells release H-2 O-2 , which may evaporate from the airways surface and be detected in expired breath condensate. We tested whether patients with systemic sclerosis exhale more H-2 O-2 than healthy subjects and whether breath condensate H-2 O-2 levels correlate with some clinical parameters. Materials and methods H-2 O-2 was measured fluorimetrically in the expired breath condensate of 27 patients (22 women, five men, mean age 49 +/- 13.1 years) with systemic sclerosis and 27 age- and sex- matched healthy controls. Results Exhaled H-2 O-2 levels were 3.5-fold higher (0.88 +/- 0.62 muM vs. 0.25 +/- 0.17 muM, P < 0.001) in the patients with systemic sclerosis than in the controls. Treatment with cyclophosphamide and/or prednisone (29 +/- 50 months, range 3-168 months) did not significantly decrease H-2 O-2 exhalation (0.78 +/- 0.50 muM, n = 10 vs. 0.94 +/- 0.67 muM, n = 17, P > 0.05). No significant difference was found between patients with limited and diffuse scleroderma (1.03 +/- 0.69 muM, n = 17 vs. 0.63 +/- 0.41 muM, n = 10, P > 0.05). H-2 O-2 levels correlated with disease duration (r = 0.38, P < 0.05) and time from the first Raynaud's episode (r = 0.44, P < 0.05). Conclusions Patients with systemic sclerosis exhale more H-2 O-2 than healthy controls, suggesting involvement of reactive oxygen species in disease processes. Lack of significant intergroups differences in H-2 O-2 levels may have resulted from the small number of patients analyzed.
引用
收藏
页码:274 / 279
页数:6
相关论文
共 43 条
[11]   ANTIOXIDANT MACROMOLECULES IN THE EPITHELIAL LINING FLUID OF THE NORMAL HUMAN LOWER RESPIRATORY-TRACT [J].
CANTIN, AM ;
FELLS, GA ;
HUBBARD, RC ;
CRYSTAL, RG .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (03) :962-971
[12]   A CONTROLLED-STUDY OF OXYGEN METABOLITE RELEASE BY ALVEOLAR MACROPHAGES FROM CHILDREN WITH INTERSTITIAL LUNG-DISEASE [J].
CLEMENT, A ;
CHADELAT, K ;
MASLIAH, J ;
HOUSSET, B ;
SARDET, A ;
GRIMFELD, A ;
TOURNIER, G .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (06) :1424-1428
[13]  
CRAPO RO, 1981, AM REV RESPIR DIS, V123, P185
[14]   Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma [J].
Davas, EM ;
Peppas, C ;
Maragou, M ;
Alvanou, E ;
Hondros, D ;
Dantis, PC .
CLINICAL RHEUMATOLOGY, 1999, 18 (06) :455-461
[15]   European multicentre study to define disease activity criteria for systemic sclerosis.: I.: Clinical and epidemiological features of 290 patients from 19 centres [J].
Della Rossa, A ;
Valentini, G ;
Bombardieri, S ;
Bencivelli, W ;
Silman, AJ ;
D'Angelo, S ;
Cerinic, MM ;
Belch, JF ;
Black, CM ;
Becvar, R ;
Bruhlman, P ;
Cozzi, F ;
Czirják, L ;
Drosos, AA ;
Dziankowska, B ;
Ferri, C ;
Gabrielli, A ;
Giacomelli, R ;
Hayem, G ;
Inanc, M ;
McHugh, NJ ;
Nielsen, H ;
Scorza, R ;
Tirri, E ;
van den Hoogen, FHJ ;
Vlachoyiannopoulos, PG .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (06) :585-591
[16]  
ELBIM C, 1995, EUR CYTOKINE NETW, V6, P113
[17]   Effects of calcium blockers on the cytosolic calcium, H2O2 production and elastase release in human neutrophils [J].
Haga, Y ;
Dumitrescu, A ;
Zhang, Y ;
StainMalmgren, R ;
Sjoquist, PO .
PHARMACOLOGY & TOXICOLOGY, 1996, 79 (06) :312-317
[18]   STRUCTURAL FEATURES OF INTERSTITIAL LUNG-DISEASE IN SYSTEMIC-SCLEROSIS [J].
HARRISON, NK ;
MYERS, AR ;
CORRIN, B ;
SOOSAY, G ;
DEWAR, A ;
BLACK, CM ;
DUBOIS, RM ;
TURNERWARWICK, M .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (03) :706-713
[19]  
KAHALEH MB, 1986, CLIN EXP RHEUMATOL, V4, P367
[20]   Lung involvement in systemic sclerosis (scleroderma): Relation to classification based on extent of skin involvement or autoantibody status [J].
Kane, GC ;
Varga, J ;
Conant, EF ;
Spirn, PW ;
Jimenez, S ;
Fish, JE .
RESPIRATORY MEDICINE, 1996, 90 (04) :223-230